In TPP, Pharma Seeks Time-Based IP Transitions; Hints At Biologics Flexibility

CANBERRA -- U.S. brand-name drug companies are taking the position that they will only support a Trans-Pacific Partnership (TPP) agreement that includes a time-based transition period for implementing intellectual property (IP) obligations rather than one linked to development indicators, but are willing to be flexible on their demand for 12 years of data exclusivity for biologic drugs, according to industry sources. In exchanges with government officials here and elsewhere, brand-name industry representatives are driving home the point that a reasonable...